The key products of Pharmatest in oncology are various orthotopic and metastasis models that have a high clinical predictivity. In addition, Pharmatest offers in vitro cell viability studies and subcutaneous xenograft models. Subcutaneous xenografts are cheap, fast and simple to perform, and therefore excellent tools for preliminary efficacy studies. However, Pharmatest recommends to use subcutaneous xenografts only for selecting compounds for further testing in clinically more predictive models, such as our orthotopic and metastasis models.
All cancer cell lines listed in the In vitro assays page are available for use in subcutaneous animal models. In addition, Pharmatest offers the human cancer cell lines listed in the table below forin vitro cell viability assays, and some of them have been validated for use also in subcutaneous xenograft models. Pharmatest does not currently have validated orthotopic or metastasis models with these cell lines.
Cell line | Cancer | In vitro | Subcutaneous |
T24 | Bladder | X | X |
786-O | Renal | X | X |
Granta-519 | B cell lymphoma | X | X |
HT1080 | Fibrosarcoma | X | X |
JJN-3 | Multiple myeloma | X | |
L-363 | Multiple myeloma | X | |
RPMI-8226 | Multiple myeloma | X | |
LP-1 | Multiple myeloma | X |